Physician profile
Michael J Giuffrida
NPI 1760586622
$15,266.11
in general payments reported to CMS, 2019-2025
10 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $21.80 · 2021: $88.96 · 2022: $269 · 2023: $44.86 · 2024: $1,665 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,216 · Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,216.39 |
| Food and Beverage | $839.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $14,116.95 | 2019-2025 | |
| Tela Bio, INC. | $320.83 | 2024-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Cumberland Pharmaceuticals, INC. | $195.67 | 2019-2022 | |
| Medtronic, INC. | $166.45 | 2022 | |
| Covidien LP | $113.63 | 2019 | |
| W. L. Gore & Associates, INC. | $104.13 | 2019 | |
| Merck Sharp & Dohme LLC | $99.99 | 2022-2025 | Bridion, Verquvo |
| Solta Medical, A Division of Bausch Health US, LLC | $65.54 | 2024 | |
| Chiesi USA, INC. | $42.55 | 2022-2023 | Cleviprex |
| Integra Lifesciences Corporation | $40.37 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Giuffrida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.